Loading clinical trials...
Loading clinical trials...
Galactose Supplementation for the Treatment of Patients With Mild Malformation of Cortical Development With Oligodendroglial Hyperplasia in Epilepsy (MOGHE): a Pilot Trial
Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new entity frequently associated with refractory epilepsy and neurodevelopmental disorders. Recently, it has been associated to SLC35A2 (Solute Carrier Family 35 Member A2) brain mosaic pathogenic variants. In addition, patients with germline SLC35A2 pathogenic variants improve with galactose supplementation. Therefore, the investigators aim to elucidate whether d-galactose as an add-on treatment might improve epilepsy and developmental outcomes in patients with MOGHE.
Age
2 - 20 years
Sex
ALL
Healthy Volunteers
No
Hospital Ruber Internacional
Madrid, Madrid, Comunidad de, Spain
Start Date
January 15, 2021
Primary Completion Date
September 1, 2021
Completion Date
October 1, 2021
Last Updated
April 6, 2021
8
ESTIMATED participants
D-Galactose
DIETARY_SUPPLEMENT
Lead Sponsor
Hospital Ruber Internacional
NCT06425029
NCT06304389
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05019885